← All trials
NCT05751187
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2023
- Primary completion
- Mar 30, 2026
- Completion date
- Mar 30, 2027
- First posted
- Mar 2, 2023
- Last posted
- Jul 12, 2023
- Enrollment
- 54
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- MerckCollaborator
- Jiao Tong UniversityOverall official - principal investigator
- Jiao Tong UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.